Search

Your search keyword '"Humblet Y"' showing total 370 results

Search Constraints

Start Over You searched for: Author "Humblet Y" Remove constraint Author: "Humblet Y"
370 results on '"Humblet Y"'

Search Results

7. Effect of hospital volume on quality of care and outcome after rectal cancer surgery

9. Risk adjusted benchmarking of abdominoperineal excision for rectal adenocarcinoma in the context of the Belgian PROCARE improvement project

27. A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer

28. Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)

30. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients

31. PET, CT and tumor markers in the evaluation of postchemotherapy residuals in metastatic germ-cell tumors

32. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

33. Characterization of the immunoscore of synchronous resected primary tumor and liver colorectal cancer metastases

34. Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial

35. Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)

36. Lymph node ratio and surgical quality are strong prognostic factors of rectal cancer: results from a single referral centre

38. New drugs in medical oncology: new difficulties to distinguish drug-induced side effects from cancer complications: a case-report

40. La Resistance A La Chimiotherapie: Progres Recents

41. Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone

42. Cavitation of lung metastases induced by regorafenib is associated with radiological response in metastatic colorectal cancer: data from the phase III correct study

43. Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months

44. 2015 Cavitation of lung metastases induced by regorafenib in patients with colorectal carcinoma: Data from the phase III CORRECT study

45. 2154 Metastatic colorectal cancer has heterogeneous immune microenvironment and mutational expression

46. Subgruppenanalyse von Patienten mit metasiertem kolorektalen Karzinom (mKRK), die unter Regorafenib (REG) in der CORRECT-Studie ein progressionsfreies Überleben von mehr als 4 Monaten hatten

49. Final Results of a Randomized Phase Ii Study with Neo-Adjuvant Triplet or Doublet Therapy, Radiation and Total Mesorectal Excision for Locally Advanced Rectal Cancer: Axe Beam

50. B Cells (Cd20+) Associated to Tumor Infiltrating Cytotoxic T-Cells Observed on Resected Liver Colorectal Metastases (Lcm) are Prognostic

Catalog

Books, media, physical & digital resources